Association of Plasma Osteoprotegerin with Adiponectin and Difference according to Obesity in Men with Metabolic Syndrome

Woori Na; Cheongmin Sohn

doi:10.5720/kjcn.2011.16.6.762

Journal List > Korean J Community Nutr > v.16(6) > 1038337

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Na and Sohn: Association of Plasma Osteoprotegerin with Adiponectin and Difference according to Obesity in Men with Metabolic Syndrome

Original Article

Korean Journal of Community Nutrition

Korean Journal of Community Nutrition 2011; 16(6): 762-770.

Published online: 31 December 2011

DOI: https://doi.org/10.5720/kjcn.2011.16.6.762

Association of Plasma Osteoprotegerin with Adiponectin and Difference according to Obesity in Men with Metabolic Syndrome

Woori Na, Cheongmin Sohn

Major in Food and Nutrition, Wonkwang University, Iksan, Korea.

Corresponding author: Cheongmin Sohn, Major in Food and Nutriton, Wonkwang University, 344-2 Sinyong-Dong, Iksan, Jeonbuk 570-749, Korea. Tel: (063) 850-6656, Fax: (063) 850-7301, ccha@wku.ac.kr

Received 10 November 2011 Revised 2 December 2011 Accepted 5 December 2011

Abstract

Osteoprotegerin (OPG) plays a core role in bone reformation by antagonizing the effect of receptor activator of nuclear factor κ-B ligand (RANKL), and mediates vascular calcification in cardiovascular disease patients. Thus, we aimed to examine the relationship between serum OPG levels and cardiovascular factors and inflammatory markers in metabolic syndrome patients (MS). This cross-sectional study included 96 men who visited the diet clinic between May and July 2011. Patients were classified into 2 groups based on NCEP-ATP guidelines: normal and with MS (n = 50 and 46, respectively). Physical measurements, biochemical assay were measured. Serum OPG and IL-6, diponectin and hs-CRP were assessed. MS were aged 50.02 ± 10.85 years, and normal patients 52.07 ± 9.56 years, with no significant differences. Significant differences were not observed in BMI between the 2 groups. Moreover, significant differences were not observed in serum OPG, however, the serum OPG level (4.41 ± 1.86 pmol/L) differed significantly between an overweight MS (BMI > 25) and normal patients. OPG was correlated to age (r = 0.410, p = 0.000), HDL-cholesterol (r = 0.209, p = 0.015), and log adiponectin (r = 0.175, p = 0.042). Multiple regression analyses using the enter method showed that age (β = 0.412, p = 0.000) and BMI (β = 0.265, p = 0.000) considerably affected OPG. In conclusion, out study showed that serum OPG levels are correlated with cardiovascular risk factors, such as BMI, HDL-cholesterol and adiponectin in MS and adiponectin, suggesting that serum OPG has potential as a cardiovascular disease indicator and predictor.

Keywords: osteoprotegerin, cardiovascular disease risk factors, inflammatory markers, adiponectin

Figures and Tables

Fig. 1

Difference of OPG levels between MS group and control group according to body mass index.

Table 1

General characteristics and metabolic syndrome indicators of the subjects

1) Mean ± SD, 2) BMI: Body mass index, 3) WC: Waist circumference, 4) FPG: Fasting plasma glucose, 5) HDL-Chol: High-density lipoprotein cholesterol, 6) SBP: Systolic blood pressure, 7) DBP: Diastolic blood pressure

Significantly different at ^**: p < 0.01, ^***: p < 0.001 by t-test

Table 2

Risk factors for cardiovascular disease and inflammatory markers

1) Mean ± SD, 2) LDL-Chol: Low-density lipoprotein cholesterol, 3) HOMA-IR: Homeostasis model assessment of insulin resistance, 4) IL-6: Interleukine 6, 5) hs-CRP: High-sensitivity C-reactive protein, 6) OPG: Osteoprotegerin

Significantly different at ^*: p < 0.05, ^***: p < 0.001 by t-test

Table 3

Dietary intakes of the subjects

1) Mean ± SD

2) Cho : Pro : Fat (%) : Carbohydrate : Protein : Fat (%)

Significantly different at ^*: p < 0.05 by t-test

Table 4

Relationship between OPG and cardiovascular disease risk factors and inflammatory markers

1) BMI: Body mass index, 2) SBP: Systolic blood pressure, 3) DBP: Diastolic blood pressure, 4) FPG: Fasting plasma glucose, 5) HDL-Chol: High-density lipoprotein cholesterol, 6) LDL-Chol: Low-density lipoprotein cholesterol, 7) hs-CRP: High-sensitivity C-reactive protein, 8) IL-6: Interleukine-6, 9) HOMA-IR: Homeostasis model assessment of insulin resistance

Table 5

Multiple regression of blood OPG levels on risk factors for cardiovascular disease and adiponectin

1) BMI: Body Mass Index

2) HDL-Chol: High-density lipoprotein cholesterol

References

1. Altinova AE, Toruner F, Akturk M, Bukan N, Yetkin I, Cakir N, Arslan M. Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. Scand J Clin Lab Invest. 2011. 71(4):340–343.

2. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006. 47(9):1850–1857.

3. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999. 257:79–83.

4. Ashley DT, O'Sullivan EP, Davenport C, Devlin N, Crowley RK, McCaffrey N, Moyna NM, Smith D, O'Gorman DJ. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. Metabolism. 2011. 60(7):994–1000.

5. Avignon A, Sultan A, Piot C, Elaerts S, Cristol JP, Dupuy AM. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care. 2005. 28:2176–2180.

6. Bae YJ, Kim MH. Calcium and magnesium supplementation improves serum OPG/RANKL in calcium-deficient ovariectomized rats. Calcif Tissue Int. 2010. 87(4):365–372.

7. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 1990. 65(3):168–172.

8. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001. 86(2):631–637.

9. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu WL, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998. 12(9):1260–1268.

10. Chen WJ, Rijzewijk LJ, van der Meer RW, Heymans MW, van Duinkerken E, Lubberink M, Lammertsma AA, Lamb HJ, de Roos A, Romijn JA, Smit JW, Bax JJ, Bjerre M, Frystyk J, Flyvbjerg A, Diamant M. Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol. 2011. 10:67. [Epub ahead of print].

11. Coetzee M, Haag M, Kruger MC. Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E2 and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells. J Nutr Biochem. 2007. 18(1):54–63 .

12. Esposito K, MarfellaR , Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004. 292(12):1440–1446.

13. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes. 1992. 41:Suppl 2. 97–101.

14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972. 18(6):499–502.

15. Gannagé-Yared MH, Fares F, Semaan M, Khalife S, Jambart S. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf). 2006. 64(6):652–658.

16. Gannage-Yared MH, Yaghi C, Habre B, Khalife S, Noun R, Germanos-Haddad M, Trak-Smayra V. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol. 2008. 158(3):353–359.

17. Hong YM, Song YW, Kim HS, Park HS, Min JH, Jung JW, Kim NS, Noh CI. Metabolic syndrome in the overweight and obese adolescents and the impact of obesity on the cardiovascular system. Korean J Pediatr. 2009. 52(10):1109–1118.

18. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000. 20(6):1595–1599.

19. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002. 106(10):1192–1194.

20. Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson JE, Ehrlich J, Eckel RH, Rewers M. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005. 111(6):747–753.

21. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002. 8:731–737.

22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985. 28(7):412–419.

23. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000. 192(4):463–474.

24. Nabipour I, Kalantarhormozi M, Larijani B, Assadi M, Sanjdideh Z. Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. Metabolism. 2010. 59(5):742–747.

25. Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C, Feingold KR. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology. 1995. 136(5):2143–2149.

26. O'Sullivan EP, Ashley DT, Davenport C, Devlin N, Crowley R, Agha A, Thompson CJ, O'Gorman D, Smith D. Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes. Diabetes Metab Res Rev. 2010. 26(6):496–502.

27. Park JY, Kim JW, Kim JM, Han Y, Park SK, Mok JY, Park MK, Lee HJ, Kim DK. Adiponectin Concentrations in Type 2 Diabetic Patients with or without Metabolic Syndrome. Korean Diabetes J. 2008. 32(3):224–235.

28. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001. 286(3):327–334.

29. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000. 342(12):836–843.

30. Rude RK, Gruber HE, Wei LY, Frausto A. Immunolocalization of RANKL is increased and OPG decreased during dietary magnesium deficiency in the rat. Nutr Metab (Lond). 2005. 2(1):24.

31. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003. 88(3):1024–1028.

32. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997. 89(2):309–319.

33. Stenvinkel P, Heimburger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: Association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis. 2002. 39(2):274–282.

34. Wu XY, Wu XP, Xie H, Zhang H, Luo XH, Liu SP, Peng YQ, Dai RC, Liao EY. Relationship between age-related reference values of serum osteoprotegerin and leptin in native Chinese women and compared with those in women of other races. Clin Chim Acta. 2008. 389(1-2):72–78.

TOOLS

Similar articles